Legend Biotech's stock took a sharp hit on Monday, falling more than 14%, even as RBC Capital Markets issued a bullish note on the company's early-stage in vivo CAR-T therapy program. The investment bank said the market is underpricing the promise of the technology, which could eventually transform how cell therapies are made and delivered.
What is in vivo CAR-T therapy?
CAR-T therapy is a type of cancer treatment that engineers a patient's own immune cells to recognize and attack tumors. Today's approved CAR-T therapies, such as those from Gilead and Bristol Myers Squibb, are made by removing a patient's T cells, genetically modifying them in a lab, and then infusing them back into the body. This process is complex, expensive, and time-consuming.
Legend Biotech's in vivo approach aims to skip the lab step entirely. Instead of removing cells, the therapy would deliver genetic instructions directly into the patient's body, reprogramming immune cells on the spot. If successful, this could make CAR-T treatment faster, cheaper, and more accessible to a wider range of patients.
RBC's take on the data
RBC said the early data from Legend's in vivo program "clearly validates" the underlying concept. The bank noted that more follow-up data could be released later this year, and it outlined a possible earliest path to market. However, RBC did not specify a timeline or valuation target in the brief.
The positive commentary comes against a backdrop of growing interest in next-generation cell therapies. Several biotech companies, including those attracting hedge fund attention in healthcare, are racing to develop in vivo approaches. Legend's early results suggest it may be among the leaders in this emerging field.
Why the stock fell
Despite RBC's endorsement, the stock dropped more than 14% on Monday. The decline may reflect broader market dynamics or profit-taking after recent gains. It could also indicate that investors are cautious about early-stage data, which often carries high uncertainty. For a biotech stock, a single day's move of this magnitude is not unusual, especially when the news involves preclinical or early clinical results.
Legend Biotech is also known for its approved CAR-T therapy, Carvykti, which is co-developed with Johnson & Johnson. The in vivo program is separate and much earlier in development, meaning any potential revenue is years away. Investors may be weighing the long-term promise against the near-term risks and costs.
What it means for investors
For everyday investors, the key takeaway is that early-stage biotech data can be a double-edged sword. Positive analyst commentary can provide a floor, but it does not guarantee the stock will rise. The market often prices in a wide range of outcomes, and a single analyst's view is just one data point.
Investors should also understand that in vivo CAR-T is still experimental. While the concept is exciting, many therapies fail in later-stage trials. Legend's program is likely years away from any regulatory filing, and the path to approval is uncertain. Companies in this space often see volatile stock moves as trial results are released.
That said, if the technology works, it could be a game-changer for cancer treatment and for Legend's business. The company already has a commercial product in Carvykti, which provides some revenue and a platform for further innovation. The in vivo program could eventually complement that franchise.
Broader context
The biotech sector has been under pressure in recent months due to higher interest rates and a cautious funding environment. However, markets are now awaiting the next Federal Reserve decision, and a potential rate cut could boost riskier assets like biotech stocks. Legend's stock move on Monday may also reflect sector-wide sentiment rather than company-specific news.
RBC's note is a reminder that analyst opinions can diverge sharply from market action. While the bank sees value, the broader market is selling. For long-term investors, such disconnects can sometimes create opportunities, but they also underscore the importance of diversification and a clear investment horizon.
Legend Biotech will likely remain a stock to watch as more data from its in vivo program emerges. The next catalyst could be the follow-up data RBC mentioned, which might provide a clearer picture of the therapy's potential. Until then, investors should expect continued volatility.
